drugset / Trial / NCT04052061
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
NaSequentialOpen-labelTreatment
Summary
Phase 1 study to assess the safety, preliminary efficacy of CD19 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with diffuse large B-cell lymphoma (DLBCL).
Timeline
- Start
- 2019-09-16
- Primary completion
- 2021-09-18
- Completion
- 2022-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 t-haNK | Cell therapy | — | — |